Treatment with both dabrafenib and trametinib (MEK inhibitor) enhances the therapeutic efficacy and leads to an ORR of 64% and median PFS of 14.6 months in V600E BRAF-mutated NSCLC patients based on independent review committee assessment [11]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.